ELEKTA B SHS UNSP/ADR - EKTAY STOCK NEWS

Elekta has invested heavily in digitized service solutions to ensure timely radiotherapy for cancer patients. Their IntelliMax® system remotely monitors over 80% of installed linear accelerators, preventing issues and ensuring seamless operations. Recently, Elekta received its first patent for IntelliMax capabilities, which are expected to enhance serviceability and predictability in treatment systems. In 2020, IntelliMax contributed to maintaining over 200,000 patient treatment slots. This innovation aligns with Elekta's Access 2025 strategy, focusing on proactive maintenance and customer partnerships.

Elekta announced that its Elekta Harmony radiation therapy system has received U.S. FDA 510(k) clearance, enabling U.S. clinics to treat a broad range of indications.

The system balances productivity and precision, addressing the increasing cancer burden, exacerbated by Covid-19 delays in diagnoses.

Key features include reduced patient setup time by up to 50%, workflow enhancements, and a versatile design for challenging treatments like SBRT, aimed at enhancing treatment access across networks.

Elekta outlined its mid-term strategy, Access 2025, during its Capital Markets Day on June 7, 2021. CEO Gustaf Salford emphasized the need for over 300 million cancer patients to access radiation therapy, particularly in emerging markets where demand exceeds the current supply of 14,000 linear accelerators. The strategy focuses on innovation, customer integration, and enhancing radiation therapy technology, supported by reinforced ESG goals. CFO Johan Adebäck projected more than 7% net sales growth annually until 2024/25, indicating a positive financial outlook.

Elekta and Royal Philips have expanded their strategic partnership to enhance cancer care through precision oncology solutions. This collaboration focuses on improving magnetic resonance (MR)-guided adaptive radiation therapy, enabling quicker tumor visualization, optimal treatment strategies, and effective therapy delivery. The partnership aims to bolster personalized treatments for patients while lowering healthcare costs. Elekta's President and CEO, Gustaf Salford, emphasizes the potential for better cancer outcomes through integrated systems. The agreement showcases a commitment to advancing oncology technologies.

Elekta has achieved a significant milestone by selling its 100th Elekta Unity MR-Linac unit, ordered by St George's Hospital in Christchurch, New Zealand. This device, enhancing radiation therapy with real-time MRI imaging, is now present in 14 countries. CEO Gustaf Salford highlighted its clinical benefits and rapid sales exceeding initial expectations. The Unity unit will provide advanced cancer care in New Zealand, contributing to St George's vision of excellence. With over 500 abstracts published, Elekta Unity is setting a new standard in MR-guided radiotherapy.

Elekta reported strong order growth in Q4 2021, totaling SEK 5,379 M (up 18% in constant currency). Despite challenges due to Covid, net sales rose slightly to SEK 3,667 M. Full-year performance showed gross order intake at SEK 17,411 M (up 6%) and net sales at SEK 13,763 M. EBITA increased to SEK 2,709 M with a margin of 19.7%. A proposed dividend of SEK 2.20 per share was announced. The company aims for over 7% net sales CAGR until 2024/25, and plans to expand EBIT margins.

Elekta will host a digital Capital Markets Day (CMD) on June 7, 2021, allowing investors and analysts to learn about the company's strategy for cancer care. The event, featuring CEO Gustaf Salford and CFO Johan Adebäck, will discuss Elekta's innovations and ESG initiatives. It will be broadcast live, starting at 14:00 CEST and concluding at 16:45 CEST, including a Q&A session. Attendees must register by June 4, 2021, with recordings made available afterward.

Elekta will present its fiscal year 2020/21 results on May 28, 2021, at 10:00 a.m. CEST. The year-end report will be released earlier at 7:30 a.m. CET. Key executives, including President and CEO Gustaf Salford and CFO Johan Adebäck, will lead the presentation, followed by a Q&A session. Participants can join via a live webcast or a phone conference, with specific numbers provided for various countries. This event is part of Elekta's commitment to transparency and investor relations.

Elekta AB held an Extraordinary General Meeting on April 16, 2021, due to Covid-19, with resolutions adopted via advance postal vote. The Board of Directors proposed an extra dividend of SEK 0.90 per share, totaling approximately MSEK 334. The record date for this dividend is set for April 20, 2021, with expected payout on April 23, 2021. For complete details, refer to the company's official website.